Eli Lilly and Company (LLY)vsSo-Young International Inc (SY)
LLY
Eli Lilly and Company
$966.99
+1.95%
HEALTHCARE · Cap: $869.41B
SY
So-Young International Inc
$2.95
-2.96%
HEALTHCARE · Cap: $297.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 4643% more annual revenue ($72.25B vs $1.52B). LLY leads profitability with a 35.0% profit margin vs -15.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SY
Hold40
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.7x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.8% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SY
The primary concerns for SY are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
SY carries more volatility with a beta of 2.13 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 40/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?